
ACT Brief: Zip Code Trial Access, Smaller Biotech APAC Perceptions, and Pimjetmi Tumor Approval
2026-11-13
0:00
1:30
In today’s ACT Brief, we examine how ZIP code shapes trial availability and enrollment, why smaller biotechs hold outdated views of APAC sites, and how FDA approved Pimjetmi for symptomatic tenosynovial giant cell tumor.
Fler avsnitt från "Applied Clinical Trials"



Missa inte ett avsnitt av “Applied Clinical Trials” och prenumerera på det i GetPodcast-appen.








